Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide ... tirzepatide achieved at least 25% body weight loss compared to 16.1% of those receiving ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Drugmaker Eli Lilly announced promising Phase 3 study results ... diabetes and weight loss. The drug is in the same class of GLP-1 medications as Ozempic, Wegovy, Mounjaro, and Zepbound ...

The World Health Organization (WHO) on Thursday announced its support for weight-loss drugs in adults globally. The organization plans to back GLP-1s like Wegovy and Zepbound to treat obesity in ...

Medications targeting weight loss like Wegovy and Zepbound are part of a relatively ... as not only life-changing but also lifesaving. The results have led to a surge in popularity in recent ...

To get Zepbound from Ro, you must join the company’s Body Program. This program offers prescription weight loss drugs ... review their history and lab results. If they determine the medication ...

Orforglibron, a pill form of GLP-1 weight loss injections ... Mounjaro and Zepbound, the pharmaceuticals giant said Thursday. Lilly announced the results of its first of seven clinical trials ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

This is partly thanks to Zepbound ... weight loss option, and Eli Lilly might have just done it. In a phase 3 study, orforglipron, a once-daily weight management candidate, delivered excellent ...

After reviewing your results, a licensed healthcare professional reaches out to discuss whether you’re eligible for Zepbound or another weight loss medication. Zepbound is available in both ...